Gilead Sciences (NASDAQ:GILD – Get Free Report) posted its earnings results on Thursday. The biopharmaceutical company reported $2.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.19 by $0.36, FiscalAI reports. The firm had revenue of $8.30 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative return on equity of 1.70% and a negative net margin of 12.47%. The business’s revenue was up 6.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.47 earnings per share.
Here are the key takeaways from Gilead Sciences’ conference call:
- Strong third-quarter execution: Base business sales rose 16% year over year to $8.2 billion, led by HIV products, TRODELVY, and Livdelzi. Gilead raised its 2026 base-business revenue guidance by $900 million at the midpoint.
- HIV momentum remained robust, with sales up 18% and BIKTARVY reaching a record 53% U.S. treatment share. Yeztugo sales reached $305 million for the quarter and are tracking toward approximately $1 billion for the full year, while the Bixlenvo launch is reportedly progressing ahead of comparable launches.
- The company highlighted a broadening growth pipeline, including a potential 2027 filing for once-weekly oral HIV treatment, additional long-acting HIV options, seven clinical-stage oncology ADC programs, and 13 inflammation programs. Management also expects a potential anito-cel approval in December for relapsed or refractory multiple myeloma.
- CMS set BIKTARVY’s Medicare price at $2,600 per 30-day supply, approximately 38% below list price. Gilead preliminarily estimates a roughly $1.5 billion net revenue impact in 2028, including spillover effects across Medicaid, 340B, and other U.S. channels.
- Cell therapy sales declined 18% year over year because of competitive pressure, and the PALISADES-1 and -2 studies of KITE-753 are on partial clinical hold while the company investigates higher-grade ICANS differences between trial phases. Gilead said there were no patient deaths but paused the studies pending further review.
Gilead Sciences Trading Up 3.1%
GILD opened at $170.68 on Friday. The stock has a market cap of $211.63 billion, a PE ratio of -54.01 and a beta of 0.31. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. The business has a 50 day moving average of $150.87 and a 200-day moving average of $139.79. Gilead Sciences has a 52 week low of $114.02 and a 52 week high of $175.65.
Gilead Sciences Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be given a $0.82 dividend. The ex-dividend date of this dividend is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 1.9%. Gilead Sciences’s dividend payout ratio is currently -122.85%.
Analysts Set New Price Targets
Several analysts recently weighed in on the stock. TD Cowen lifted their price target on shares of Gilead Sciences from $160.00 to $175.00 and gave the company a “buy” rating in a report on Friday. Wall Street Zen upgraded shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Saturday, September 19th. Jefferies Financial Group restated a “buy” rating and issued a $185.00 price objective on shares of Gilead Sciences in a report on Friday, October 23rd. Cantor Fitzgerald raised their target price on shares of Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a research report on Friday. Finally, Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research note on Friday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of “Moderate Buy” and an average price target of $169.19.
Get Our Latest Research Report on GILD
Insider Activity at Gilead Sciences
In other Gilead Sciences news, insider Johanna Mercier sold 3,000 shares of the firm’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $156.22, for a total transaction of $468,660.00. Following the completion of the transaction, the insider owned 113,684 shares of the company’s stock, valued at approximately $17,759,714.48. This trade represents a 2.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer owned 161,096 shares in the company, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 111,000 shares of company stock valued at $15,877,860 over the last ninety days. Insiders own 0.30% of the company’s stock.
Key Stories Impacting Gilead Sciences
Here are the key news stories impacting Gilead Sciences this week:
- Positive Sentiment: Q3 results exceeded expectations. Gilead reported adjusted earnings of $2.55 per share versus the $2.19 consensus estimate, while revenue rose 6.8% year over year to $8.30 billion, beating expectations by roughly $500 million. Gilead Sciences Q3 earnings and revenues top estimates
- Positive Sentiment: Management raised its 2026 product-sales outlook to approximately $31.0 billion-$31.3 billion, up from $30.1 billion-$30.4 billion, following strong demand for HIV treatments. Base-business sales excluding Veklury reportedly increased 16%, the company’s strongest growth in more than a decade. Gilead Sciences lifts sales guidance on HIV portfolio strength
- Positive Sentiment: Key growth products performed well. Biktarvy continued to drive HIV sales, while Trodelvy revenue rose 41.7% year over year to $506 million. Livdelzi also contributed to growth, aided by a pan-Canadian public reimbursement agreement that could broaden patient access. GILD beats Q3 earnings on HIV strength and Trodelvy sales growth
- Positive Sentiment: Analyst sentiment improved materially. Citigroup, Scotiabank, Morgan Stanley, Truist, Wells Fargo, Needham and Cantor Fitzgerald all raised their price targets, with several maintaining buy or overweight-equivalent ratings. Targets generally range from $175 to $200. Analysts increase forecasts after upbeat Q3 results
- Neutral Sentiment: Gilead declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a stated yield of about 1.9%.
- Negative Sentiment: Longer-term pricing and concentration risks remain. Medicare pricing is expected to reduce Biktarvy’s price by approximately 38% beginning in 2028, potentially cutting annual revenue by about $1.5 billion. Analysts also note that oncology and immunology growth remains less developed, while some coverage characterizes the valuation as demanding after the rally. Gilead hikes 2026 sales outlook and discusses Biktarvy pricing
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.
Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.
Featured Stories
- Five stocks we like better than Gilead Sciences
- Can Microsoft Turn a Leaner Workforce and Record AI Spending Into Bigger Profits?
- Why JFrog Could Be the Software Infrastructure Company to Beat in the AI Boom
- The Factories Behind AI Servers Just Raised Their Outlooks—3 Contract Manufacturers to Watch
- MarketBeat Week in Review – 10/26 – 10/30
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
